Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
MET is a receptor tyrosine kinase known for its pleiotropic effects in tumorigenesis. Dysregulations of MET expression and/or signaling have been reported and determined to be associated with inferior outcomes in breast cancer patients rendering MET a versatile candidate for targeted therapeutic intervention. Crizotinib is a multi-targeted small-molecule kinase inhibitor for MET, ALK, and ROS1 kinases. This study evaluated the anti-proliferative, cytotoxic, anti-migratory, and anti-invasive effects of crizotinib in breast cancer cells in vitro. Cell viability was assessed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. In vitro wound-healing assay was used to examine the effect of crizotinib on breast cancer cell migration. The expressions of Ki-67, MET, and phospho-MET receptors were characterized using immunofluorescence staining. Results showed that crizotinib has significant anti-proliferative activity on all mammary tumor cells with IC 50 values of 5.16, 1.5, and 3.85 µM in MDA-MB-231, MCF-7, and SK-BR-3 cells, respectively. Crizotinib induced cytotoxic effects in all breast cancer cells examined. Combined treatment of small dose of crizotinib with paclitaxel or doxorubicin exhibited a highly synergistic inhibition of growth of MDA-MB-231 and MCF-7 cells with combination index values <1 while no significant effect was observed in SK-BR-3 cells compared with individual compounds. Treatment with crizotinib demonstrated a remarkable reduction in the expression of Ki-67 protein in all 3 tested cell lines. Crizotinib inhibited migration and invasion of MDA-MB-231 cells in a dose-dependent fashion. Crizotinib reduced MET receptor activation in MDA-MB-231 cells when treated at effective concentrations. In conclusion, crizotinib suppressed proliferation, migration, and invasion of breast cancer cells in vitro. The results of this study demonstrated that combined treatment of crizotinib with chemotherapeutic agents resulted in a synergistic growth inhibition of specific breast cancer cell lines. Keywords: crizotinib, breast cancer, MET receptor, chemotherapy, migration, invasion
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Crizotinib is a receptor tyrosine kinase inhibitor that inhibits the growth, migration, and invasion of breast cancer cells in preclinical studies43,44.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [43]
In the citing paper
“Crizotinib is a receptor tyrosine kinase inhibitor showing tumor-reducing effects in vitro and in vivo43,44. It is now in a phase 2 clinical trial for treating patients with TNBC (ClinicalTrials.gov Identifier: NCT03620643).”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Matteucci, E., Bendinelli, P., & Desiderio, M. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp080 · Cited by 82
RetractedMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 3×
“where X is the IC 50 value of the compound when used alone for cell growth studies, and Xc is the IC 50 value for the same compound when used in combination.(38,39) Isobologram analysis is a graphical method to evaluate the effect of equally effective concentration pairs for a singleeffect level.”
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Choosing the right cell line for breast cancer research
Holliday, D. L., & Speirs, V. (2011) · Breast Cancer Research · doi:10.1186/bcr2889 · Cited by 1,541
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Breast cancer: origins and evolution
Polyak, K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33295 · Cited by 697
An Overview of Drug Combination Analysis with Isobolograms
Tallarida, R. J. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104117 · Cited by 505
c-MET as a potential therapeutic target and biomarker in cancer
Sierra, J. R., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 365
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ypdi.2015.02.054 · Cited by 353
Kazandjian, D., Blumenthal, G. M., Chen, H.-Y., He, K., Patel, M., Justice, R., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0241 · Cited by 286
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3774 · Cited by 273
Luminal-B breast cancer and novel therapeutic targets
Tran, B., & Bedard, P. L. (2011) · Breast Cancer Research · doi:10.1186/bcr2904 · Cited by 249
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 243
Breast cancer molecular subtypes: from TNBC to QNBC.
Hon, J. D., Singh, B., Şahin, A. A., Du, G., Wang, J., Wang, V. Y., Deng, F., Zhang, D. Y., Monaco, M. E., & Lee, P. (2016) · PubMed · Cited by 242
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Yardley, D. A. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/137414 · Cited by 216
Targeting the HGF/Met signalling pathway in cancer
Cecchi, F., Rabe, D. C., & Bottaro, D. P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.028 · Cited by 209
Finkelstein, S. D., Sayegh, R., Christensen, S., & Swalsky, P. A. (1993) · Cancer · doi:10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n · Cited by 204
Ponzo, M. G., Lesurf, R., Petkiewicz, S., O'Malley, F. P., Pinnaduwage, D., Andrulis, I. L., Bull, S. B., Chughtai, N., Zuo, D., Souleimanova, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810402106 · Cited by 203
Proliferation index as a prognostic marker in breast cancer
Veronese, S. M., Gambacorta, M., Gottardi, O., Scanzi, F., Ferrari, M., & Lampertico, P. (1993) · Cancer · doi:10.1002/1097-0142(19930615)71:12<3926::aid-cncr2820711221>3.0.co;2-2 · Cited by 201
The emerging role of MET/HGF inhibitors in oncology
Scagliotti, G. V., Novello, S., & von Pawel, J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.02.001 · Cited by 200
Crizotinib: A comprehensive review
Prabhash, K., Noronha, V., Joshi, A., Desai, S., & Sahu, A. (2013) · South Asian Journal of Cancer · doi:10.4103/2278-330x.110506 · Cited by 176
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159
Bellon, S. F., Kaplan-Lefko, P., Yang, Y., Zhang, Y., Moriguchi, J., Rex, K., Johnson, C. W., Rose, P. E., Long, A. M., O'Connor, A. B., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705774200 · Cited by 139
c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy
Sattler, M., & Salgia, R. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0005-4 · Cited by 130
Tyrosine kinase signalling in breast cancer
Hynes, N. E. (2000) · Breast Cancer Research · doi:10.1186/bcr48 · Cited by 128
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
Graveel, C. R., DeGroot, J. D., Su, Y., Koeman, J., Dykema, K., Leung, S., Snider, J., Davies, S. R., Swiatek, P. J., Cottingham, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810403106 · Cited by 112
Götte, M., Kersting, C., Radke, I., Kiesel, L., & Wülfing, P. (2007) · Breast Cancer Research · doi:10.1186/bcr1641 · Cited by 110
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Krytska, K., Ryles, H. T., Sano, R., Raman, P., Infarinato, N. R., Hansel, T. D., Makena, M. R., Song, M. M., Reynolds, C. P., & Mossé, Y. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0379 · Cited by 105
Zhou, W., Zhang, X., Cheng, C., Wang, F., Wang, X., Liang, Y., To, K. K. W., Zhou, W., Huang, H., & Fu, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01849.x · Cited by 101
Genomics and the mechanism of P-glycoprotein (ABCB1)
Sauna, Z. E., Kim, I., & Ambudkar, S. V. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9115-9 · Cited by 87
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis
Rho, O., Kim, D. J., Kiguchi, K., & DiGiovanni, J. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20665 · Cited by 84
Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases
Yan, S., Jiao, X., Zou, H., & Li, K. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0296-y · Cited by 81
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
Linklater, E. S., Tovar, E. A., Essenburg, C. J., Turner, L., Madaj, Z., Winn, M. E., Melnik, M. K., Körkaya, H., Maroun, C. R., Christensen, J. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12065 · Cited by 76
MET molecular mechanisms and therapies in lung cancer
Lawrence, R. E., & Salgia, R. (2010) · Cell Adhesion & Migration · doi:10.4161/cam.4.1.10973 · Cited by 69
Zhang, Z., Wang, J., Ji, D., Wang, C., Liu, R., Wu, Z., Liu, L., Zhu, D., Chang, J., Geng, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3396 · Cited by 69
İnanç, M., Özkan, M., Karaca, H., Berk, V., Bozkurt, O., Duran, A. O., Özaslan, E., Akgün, H., Tekelioğlu, F., & Elmalı, F. (2013) · Medical Oncology · doi:10.1007/s12032-013-0801-7 · Cited by 64
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav, K. P. S., Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.09.04 · Cited by 60
c-MET Inhibitors in the Treatment of Lung Cancer
Goździk-Spychalska, J., Szyszka-Barth, K., Spychalski, Ł., Ramlau, K., Wójtowicz, J., Batura‐Gabryel, H., & Ramlau, R. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0313-5 · Cited by 60
Gonzalez-Angulo, A. M., Chen, H., Karuturi, M. S., Chávez‐MacGregor, M., Tsavachidis, S., Meric‐Bernstam, F., Do, K.-A., Hortobágyi, G. N., Thompson, P. A., Mills, G. B., et al. (2012) · Cancer · doi:10.1002/cncr.27608 · Cited by 58
Andrechek, E. R., & Muller, W. J. (2000) · Breast Cancer Research · doi:10.1186/bcr56 · Cited by 57
Megiorni, F., McDowell, H. P., Camero, S., Mannarino, O., Ceccarelli, S., Paiano, M., Losty, P. D., Pizer, B., Shukla, R., Pizzuti, A., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0228-4 · Cited by 52
Cappuzzo, F., Moro‐Sibilot, D., Gautschi, O. P., Boleti, E., Felip, E., Groen, H. J. M., Germonpré, P. R., Meldgaard, P., Arriola, E., Steele, N. L., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.010 · Cited by 50
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure
Boccaccio, C., & Comoglio, P. M. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.008 · Cited by 43
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
Kim, H.-J., Yoon, A., Ryu, J., Cho, Y., Choi, J., Song, S. Y., Bang, H., Lee, J. S., Cho, W. C. S., Choi, C. H., et al. (2016) · Scientific Reports · doi:10.1038/srep38502 · Cited by 41
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
Gramantieri, L., Granito, A., & Guidetti, E. (2015) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s77038 · Cited by 37
Das, A., Cheng, R. R., Hilbert, M. L. T., Dixon-Mah, Y. N., Decandio, M. L., William, A. V., Banik, N. L., Lindhorst, S., Cachia, D., Varma, A. K., et al. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s32801 · Cited by 34
c-MET kinase inhibitors: a patent review (2011 – 2013)
Zhu, K., Kong, X., Zhao, D., Liang, Z. T., & Luo, C. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.864279 · Cited by 29
Chemotherapy: Updates and New Perspectives
Swain, S. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-30 · Cited by 29
Reversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexes
Li, J., Liu, J., Guo, N., & Zhang, X. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.039 · Cited by 29
Awazu, Y., Nakamura, K., Mizutani, A., Kakoi, Y., Iwata, H., Yamasaki, S., Miyamoto, N., Imamura, S., Miki, H., & Hori, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1011 · Cited by 28
Tallarida, R. J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6306-2_17 · Cited by 24
Current approaches to the management of Her2-negative metastatic breast cancer
Gogineni, K., & DeMichele, A. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3064 · Cited by 22
TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes?Preprint
van Amerongen, R., & Berns, A. J. M. (2006) · Genes & Development · doi:10.1101/gad.1460806 · Cited by 20
Li, E., Hu, Z., Sun, Y., Zhou, Q., Yang, B., Zhang, Z., & Cao, W. (2015) · Tumor Biology · doi:10.1007/s13277-015-4318-x · Cited by 20
c‐Met inhibition enhances chemosensitivity of human ovarian cancer cells
Wang, J., & Cheng, J. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12672 · Cited by 18
Chemotherapy: Updates and New Perspectives
Swain, S. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s5-08 · Cited by 14
Gilcrease, M. Z. (2013) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2013.07.007 · Cited by 13
Steen, N. V. D., Deben, C., Deschoolmeester, V., Wouters, A., Lardon, F., Rolfo, C. D., Germonpré, P. R., Giovannetti, E., Peters, G. J., & Pauwels, P. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i6.425 · Cited by 12
Adjuvant chemotherapy for early breast cancer.
Smith, I. E. (1983) · BMJ · doi:10.1136/bmj.287.6389.379 · Cited by 10
ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER?
Schmidt, M., & Koelbl, H. (1983) · Inpharma Weekly · doi:10.1007/bf03303844 · Cited by 9
Cited by
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
Raj, S., Kesari, K. K., Kumar, A., Rathi, B., Sharma, A., Gupta, P. K., Jha, S. K., Jha, N. K., Slama, P., Roychoudhury, S., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01503-1 · Cited by 162
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Huelse, J. M., Fridlyand, D. M., Earp, S. H., DeRyckere, D., & Graham, D. K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107577 · Cited by 108
ASGARD is a single-cell guided pipeline to aid repurposing of drugs
He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57
Balsa, L. M., Ferraresi-Curotto, V., Lavecchia, M. J., Echeverría, G. A., Piro, O. E., García‐Tojal, J., Diez, R. P., González-Baró, A. C., & León, I. E. (2021) · Dalton Transactions · doi:10.1039/d1dt00869b · Cited by 61
Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer
Li, M., Li, S., Li, Y., Li, X., Yang, G., Li, M., Xie, Y., Su, W., Wu, J., Jia, L., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114198 · Cited by 55
Metadata
- Authors
- Ayoub, N., Al-Shami, K., Alqudah, M. A. Y., & Mhaidat, N.
- Affiliations
- Jordan University of Science and Technology (JO)
- Corresponding author
- Ayoub, Nehad
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-10
- Volume
- Volume 10
- Pages
- 4869-4883
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC5634371
- OpenAlex
- W2761975835
- Cited by
- 38
- References
- 73
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Jordan University of Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- crizotinib, MET receptor tyrosine kinase, breast cancer, kinase inhibitors, antiproliferative activity, cell migration, cell invasion, paclitaxel, doxorubicin, drug synergy, combination therapy, Ki-67, MDA-MB-231 cells, MCF-7 cells, SKBR3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.